174.20MMarket Cap-1972P/E (TTM)
3.790High3.560Low237.27KVolume3.560Open3.770Pre Close866.56KTurnover0.74%Turnover RatioLossP/E (Static)47.73MShares11.76052wk High1.57P/B117.01MFloat Cap1.33052wk Low--Dividend TTM32.06MShs Float60.516Historical High--Div YieldTTM6.10%Amplitude1.330Historical Low3.652Avg Price1Lot Size
Shattuck Labs Stock Forum
Benzinga
The company observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete remission (mCR) rate of 58% and median overall survival had no...
Shattuck Labs Granted Orphan Drug Designation By FDA For SL-172154 In Acute Myeloid Leukemia
NEWS
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
Shattuck Labs, Inc. reveals preclinical data at AACR Annual Meeting 2024 showing TRIM7 inhibition can combat immune checkpoint therapy resistance. TRIM7 inhibitors may reverse acquired resistance to PD-1/L1 blockade, potentially benefiting cancer patients.
No comment yet